What Is Secretoneurin? Definition and What Research Reports
Secretoneurin is a small peptide released when the precursor protein secretogranin II is processed inside secretory granules of neurons and neuroendocrine cells. In the published literature it appears in two main roles: as an endogenous signalling peptide studied in fish and rodent neuroendocrine models, and as a circulating biomarker measured in cardiovascular, critical care and brain injury cohorts. Reported work includes biological-variation studies, prognostic analyses in infection, and identification of a derivative that inhibited CaMKIIδ activity in vitro.
Definition
Secretoneurin is a small peptide fragment produced when the larger precursor protein secretogranin II (a member of the granin family, also referred to as chromogranin C) is enzymatically cleaved inside the dense-core secretory granules of neurons, neuroendocrine cells and related secretory tissues. A 2020 review in General and Comparative Endocrinology described secretoneurin as a secretogranin-2–derived hormonal peptide present in vertebrate neuroendocrine systems, framing it as an endogenous signalling molecule rather than a synthetic drug candidate (PMID 32828813). In practice, the word "secretoneurin" is used two ways in the literature: as the name of that peptide when it is applied to cells or tissues in laboratory models, and as the name of an analyte measured in blood samples from patients.
Where the Peptide Comes From
Because granins are packaged into secretory vesicles alongside hormones and neurotransmitters, secretoneurin is co-released when those vesicles are discharged. That biology is why the peptide appears in such varied tissues. Immunohistochemical work has localised it outside the classical brain and adrenal sites: a 2018 study in Archives of Oral Biology reported secretoneurin and PE-11 immunoreactivity in human dental pulp, both of which are derived from secretogranin II (PMID 29132068). Its release into the circulation is also the reason clinical groups have treated it as a blood-borne marker of secretory or neuroendocrine activity.
This page is for educational purposes only and is not medical advice; consult a licensed physician about any question concerning health, diagnosis or treatment.
How the Term Is Used in Peptide Research
1. As an endogenous signalling peptide in neuroendocrine models
A substantial body of comparative endocrinology work has applied secretoneurin to cells or tissues to characterise what the peptide does. Researchers working in goldfish reported that secretoneurin A directly altered the proteome of radial glial cells in vitro (PMID 29559953), and a companion study in Scientific Reports reported that secretoneurin A regulated neurogenic and inflammatory transcriptional networks in goldfish radial glia (PMID 29097753). In the pituitary, a 2026 report in Biology of Reproduction described secretogranin II–derived secretoneurin stimulating luteinizing hormone secretion differentially by age and sex in ex vivo murine pituitaries (PMID 41800565). Upstream of the peptide itself, a zebrafish study reported that secretogranin II played a critical role in neurovascular modeling (PMID 29757409). Taken together, these papers are the reason the term is often encountered in discussions of neurogenesis, glial biology and reproductive endocrinology.
2. As a circulating biomarker in human cohorts
The second usage is analytical. A 2021 paper in Clinical Biochemistry characterised the biological variation of secretoneurin and described it as a novel cardiovascular biomarker implicated in arrhythmogenesis (PMID 34624255) — the kind of methodological groundwork that determines whether a marker can be interpreted reliably across repeated samples. In cardiology, a 2024 study in Cardiology examined a trans-cardiac gradient of secretoneurin in patients with Takotsubo syndrome (PMID 38663366), an approach used to explore where a circulating peptide may originate.
Outside cardiology, a 2016 study in Critical Care Medicine investigated the prognostic value of secretoneurin in critically ill patients with infections (PMID 27414477). In neonatology, researchers compared secretoneurin serum levels in healthy term neonates with levels in neonates who had hypoxic-ischaemic encephalopathy (PMID 26968040). A 2022 report in Current Neurovascular Research examined the role of serum secretoneurin levels in patients with traumatic brain injury (PMID 36284397). In all of these, the peptide was measured rather than administered.
3. As a starting scaffold for derivative chemistry
A third, newer usage treats the sequence as a template. A 2025 paper in the Journal of Cellular and Molecular Medicine reported the identification of a small secretoneurin derivative that inhibited CaMKIIδ activity (PMID 41126409). CaMKIIδ is a calcium/calmodulin-dependent kinase studied in cardiac signalling, and this line of work connects the biomarker literature on arrhythmogenesis (PMID 34624255) with a candidate molecular mechanism. It remains preclinical laboratory work.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeResearch Contexts at a Glance
| Context | Model or population studied | What the cited paper examined |
|---|---|---|
| Definition and comparative biology | Vertebrate neuroendocrine systems (review) | Secretoneurin as a secretogranin-2–derived hormonal peptide (PMID 32828813) |
| Glial and neurogenic signalling | Goldfish radial glial cells in vitro | Proteome changes (PMID 29559953) and neurogenic/inflammatory transcriptional networks (PMID 29097753) |
| Reproductive endocrinology | Ex vivo murine pituitaries | Luteinizing hormone secretion by age and sex (PMID 41800565) |
| Vascular development | Zebrafish | Role of secretogranin II in neurovascular modeling (PMID 29757409) |
| Assay and biomarker methodology | Human samples | Biological variation of secretoneurin (PMID 34624255) |
| Cardiology | Patients with Takotsubo syndrome | Trans-cardiac gradient of the peptide (PMID 38663366) |
| Critical care | Critically ill patients with infections | Prognostic value of serum levels (PMID 27414477) |
| Neonatology and neurotrauma | Term neonates; patients with traumatic brain injury | Serum levels in hypoxic-ischaemic encephalopathy (PMID 26968040) and after traumatic brain injury (PMID 36284397) |
| Tissue localisation | Human dental pulp | Secretoneurin and PE-11 immunoreactivity (PMID 29132068) |
| Derivative chemistry | Laboratory kinase assays | A small secretoneurin derivative that inhibited CaMKIIδ activity (PMID 41126409) |
Tolerability and Adverse Events: What Studies Report
The verified literature summarised here does not include human administration trials of secretoneurin, and therefore contains no adverse-event profile for the peptide given as an intervention. The human papers cited above measured endogenous concentrations in serum or plasma (PMID 34624255, PMID 27414477, PMID 36284397), while the interventional work was carried out in cell culture, fish and ex vivo pituitary tissue (PMID 29559953, PMID 41800565). Any statement about human safety, dosing or tolerability would go beyond what these papers report.
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appLimits of the Evidence
- Two literatures, one word. Biomarker papers describe a substance measured in patients; comparative endocrinology papers describe a peptide applied to cells or tissue. Conclusions do not transfer automatically between them.
- Species distance. Several of the most detailed mechanistic findings came from goldfish and zebrafish models (PMID 29097753, PMID 29757409).
- Association is not causation. Studies reporting altered serum levels in neonatal encephalopathy or traumatic brain injury described concentrations alongside clinical status (PMID 26968040, PMID 36284397), not a treatment effect.
- Derivative work is early. The CaMKIIδ inhibition finding was an identification study, not a clinical result (PMID 41126409).
References
- Secretoneurin is a secretogranin-2 derived hormonal peptide in vertebrate neuroendocrine systems (General and Comparative Endocrinology, 2020)
- Biological variation of secretoneurin; a novel cardiovascular biomarker implicated in arrhythmogenesis (Clinical Biochemistry, 2021)
- Trans-Cardiac Gradient of Secretoneurin in Patients with Takotsubo Syndrome (Cardiology, 2024)
- Prognostic Value of Secretoneurin in Critically Ill Patients With Infections (Critical Care Medicine, 2016)
- Secretoneurin Serum Levels in Healthy Term Neonates and Neonates with Hypoxic-Ischaemic Encephalopathy (Neonatology, 2016)
- The Role of Serum Secretoneurin Levels in Patients with Traumatic Brain Injury (Current Neurovascular Research, 2022)
- Identification of a Small Secretoneurin Derivative That Inhibits CaMKIIδ Activity (Journal of Cellular and Molecular Medicine, 2025)
- Secretogranin II-derived peptide secretoneurin differentially stimulates luteinizing hormone secretion by age and sex in ex vivo murine pituitaries (Biology of Reproduction, 2026)
- Secretoneurin A Directly Regulates the Proteome of Goldfish Radial Glial Cells In Vitro (Frontiers in Endocrinology, 2018)
- Secretoneurin A regulates neurogenic and inflammatory transcriptional networks in goldfish (Carassius auratus) radial glia (Scientific Reports, 2017)
- Secretogranin-II plays a critical role in zebrafish neurovascular modeling (Journal of Molecular Cell Biology, 2018)
- Secretoneurin and PE-11 immunoreactivity in the human dental pulp (Archives of Oral Biology, 2018)
Frequently asked questions
What class of molecule is secretoneurin?▾
It is a peptide, not a protein drug or steroid. Secretoneurin is generated by proteolytic cleavage of secretogranin II, a granin-family precursor stored in dense-core secretory granules. A 2020 review characterised it as a secretogranin-2-derived hormonal peptide found across vertebrate neuroendocrine systems (PMID 32828813), which is the definition most later papers use as their reference point.
Why is secretoneurin described as a cardiovascular biomarker?▾
Because clinical groups measure it in blood rather than administer it. A 2021 paper described secretoneurin as a novel cardiovascular biomarker implicated in arrhythmogenesis and characterised its biological variation (PMID 34624255), and a 2024 study examined a trans-cardiac gradient of the peptide in patients with Takotsubo syndrome to explore where circulating levels may originate (PMID 38663366).
What did researchers report in fish models?▾
Comparative endocrinology work used goldfish and zebrafish. Researchers reported that secretoneurin A directly altered the proteome of goldfish radial glial cells in vitro (PMID 29559953) and regulated neurogenic and inflammatory transcriptional networks in those cells (PMID 29097753). A separate zebrafish study reported that secretogranin II, the precursor protein, played a critical role in neurovascular modeling (PMID 29757409).
Has secretoneurin been studied in relation to hormones?▾
Yes, in tissue preparations. A 2026 report described secretogranin II-derived secretoneurin stimulating luteinizing hormone secretion differentially by age and sex in ex vivo murine pituitaries (PMID 41800565). That was isolated pituitary tissue, not whole-animal or human administration, so the study does not establish what the peptide does to reproductive hormones in people.
What is the CaMKII connection?▾
A 2025 paper reported the identification of a small secretoneurin derivative that inhibited CaMKII-delta activity in laboratory assays (PMID 41126409). CaMKII-delta is a calcium/calmodulin-dependent kinase studied in cardiac signalling, which links this chemistry work to the biomarker literature describing secretoneurin in the context of arrhythmogenesis (PMID 34624255). The finding remains preclinical.
Do studies report a safety profile for secretoneurin in humans?▾
No. The human studies summarised here measured endogenous concentrations in patient samples, such as critically ill patients with infections (PMID 27414477), neonates with hypoxic-ischaemic encephalopathy (PMID 26968040) and patients with traumatic brain injury (PMID 36284397). None administered the peptide, so no dosing or adverse-event profile can be drawn from them. This information is educational, not medical advice.
Is secretoneurin found outside the nervous system?▾
Yes. Because granins are packaged into secretory vesicles in many tissues, immunoreactivity has been mapped in non-neural sites; a 2018 study reported secretoneurin and PE-11 immunoreactivity in human dental pulp (PMID 29132068). Its wide distribution across vertebrate neuroendocrine tissues was also emphasised in the 2020 review defining the peptide (PMID 32828813).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.